Terfalin spray for external use 1% 30ml №1

Name:
Terfalin spray for nar. 1% in fl. 30ml No. 1 Main active ingredient Terbinafine Release form Spray Composition 1 g of spray contains: active substance: terbinafine hydrochloride 0.01 g; excipients: ethyl alcohol 96%, macrogols (Emulgin B2), propylene glycol (monopropylene glycol), purified water. Release form: spray for external use.
Description:
Transparent colorless liquid. Dosage of terbinafine hydrochloride 0.01 g Indications for use Superficial fungal infections of the skin caused by dermatophytes of the genus Trichophyton (T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum), Microsporum canis, Epidermophyton floccosum, versicolor versicolor caused by Pityrosporum orbiculare (Malassezia furfur ). Terfalin 1% Spray is contraindicated in patients with previously established hypersensitivity to one of the components of the drug. Use during pregnancy and lactation Controlled studies in pregnant women have not been conducted. Animal studies have shown no risk to the fetus. When applied topically, less than 5% of the applied amount of terbinafine is absorbed. During pregnancy, the cream should not be used if there are no absolute indications. Terbinafine is excreted in breast milk in small amounts. It is not known whether this small amount in mother’s milk can have a negative effect on the baby. Therefore, Terfalin should not be used in nursing mothers. Babies should not come into contact with treated skin areas. Dosage and administrationAdults: Terfalin 1% spray can be applied to cleansed and dried skin 1-2 times a day. The spray is applied to the affected and adjacent areas of the skin from a distance of 5-10 cm in an amount sufficient to thoroughly moisturize them. Dermatomycosis of the body, natural folds: 1 week 1 time per day. Dermatomycosis of the feet interdigital: 1 week 1 time per day. Multicolored deprive: 1 week 2 times a day. A decrease in the severity of clinical manifestations is usually noted in the first days of treatment. In case of irregular treatment or its premature termination, there is a risk of recurrence of the infection. If after two weeks of treatment there are no signs of improvement, you should consult a doctor. The use of the drug in the elderly There is no reason to assume that for the elderly it is necessary to change the dosage of the drug, or that they have side effects that differ from those in younger patients. Use of the drug in children The drug is not recommended for children and adolescents under 18 years of age, since the safety and efficacy of use for this age group have not been proven. In case of accidental contact of the spray with the eyes, rinse thoroughly with running water. Avoid spray inhalation. In case of accidental inhalation, seek medical advice; if any unwanted symptoms develop or persist. Side effects At the site of application of the cream, local symptoms may occur, such as itching, peeling, pain or irritation, pigmentation disorders, burning, erythema or crusts. These local symptoms must be distinguished from general hypersensitivity reactions, including rash, which require immediate discontinuation of treatment. After accidental eye contact, eye irritation may occur. In rare cases, there may be a worsening of the course of the underlying fungal infection. Below, side effects are listed by class of systems and organs in accordance with the frequency of occurrence. Frequencies are classified as follows: Very often (?1/10), often (?1/100, <1/10); infrequently (?1/1000, <1/100), rarely (?1/10000, <1/1000), very rarely (<1/10000). Within each frequency grouping, unwanted effects are presented in descending order of severity. Immune system disorders: Very rare: hypersensitivity reactions (urticaria, angioedema, anaphylactic shock). Eye disorders: Rare: eye irritation. Skin and subcutaneous tissue disorders: Common: skin peeling, itching. Uncommon: skin irritation, crusting, skin lesions, pigmentation, erythema, burning sensation. Rare: dry skin, contact dermatitis, eczema. Very rare: rash. General disorders and reactions at the injection site: Uncommon: pain or irritation at the application site. Rare: exacerbation of the underlying disease. Reporting Adverse Reactions If you experience any adverse reactions, please consult your physician. This recommendation applies to any possible adverse reactions, including those not listed in the package insert. You can also report adverse reactions to the adverse drug reactions (actions) information database, including reports of drug failures. By reporting adverse reactions, you help to get more information about the safety of the drug. OverdoseSymptoms Due to low systemic absorption, an overdose of terbinafine when applied topically is unlikely. Accidental ingestion of the contents of a vial containing 300 mg terbinafine hydrochloride in 30 ml is comparable to taking one 250 mg tablet (corresponding to the standard adult oral dose). If large amounts of terbinafine spray are inadvertently swallowed, the expected side effects are similar to those observed after an overdose of terbinafine tablets. These include headache, nausea, epigastric pain, and dizziness. In case of accidental ingestion of the contents of the vial, the alcohol content must be taken into account. Terfalin 1% spray contains 28.7% alcohol. Treatment Removal of unabsorbed substance by administration of activated charcoal and, if necessary, symptomatic and supportive therapy. Interaction with other drugs Potential interaction reactions with topical application of terbinafine hydrochloride and other drugs have not been systematically studied. However, as a precautionary measure, it is recommended not to use other drugs on the treated areas of the skin. Precautions Terfalin 1% Spray is intended for use on the skin and should not be used orally, in the eye, or intravaginally. In case of accidental contact of the cream with the eyes, they should be immediately rinsed thoroughly under running water. The medicinal product contains propylene glycol, ethyl alcohol and may cause skin irritation. Do not apply the drug to the skin of the face. If irritation or hypersensitivity occurs, the drug should be discontinued. Affected areas of the skin should not be covered with tight clothing. Patients with foot lesions should wear loose and well-ventilated shoes. Socks should be changed at least once a day. For optimal clinical effect, the recommended treatment period must be followed. After using the drug, wash your hands to prevent the spread of infection. Storage conditions Store at a temperature not exceeding 25 ° C in the original packaging. Keep the drug out of the reach and sight of children. Buy Terfalin spray for external use 1% 30ml №1